“Addressing Challenges in Cell Therapy & Transplant” featured Dr. Avinash Desai, CMO of Actinium Pharmaceuticals, Inc., Rachelle J., President & CEO of Akari Therapeutics, Plc, Timothy E. Morris, COO & CFO of Humanigen, and Ronald Martell, CEO of Jasper Therapeutics. The panel was moderated by Kristen Kluska and Pete Stavropoulos.

• Actinium Pharmaceuticals highlighted its lead product Iomab-B, where Phase 3 results in patients with relapsed or refractory acute myeloid leukemia (AML) are guided to be reported in 4Q22.

• Akari Therapeutics discussed its progress with lead therapy nomacopan, which is in Phase 3 development for severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA).

• Humanigen is focused on preventing and treating an immune hyper-response called ‘cytokine storm’ and discussed its Lenzilumab first-in-class antibody.

• Discussions highlighted Jasper Therapeutics’ lead candidate JSP191’s consistent activity across various populations and conditioning regimens that may enable broad utility in hematopoietic stem cell transplant, its potential as a disease modifying monotherapy agent in lower risk MDS, and additional indications it could pursue.

#Cantorconferenceseries #Oncology #Hematology #Hemeonc #Cantorfitzgerald #Cantorhealthcare